SCHEMBL291408

SCHEMBL291408

N#CC(=C(C(=O)O)c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 4/20 0.41
CES1 P23141 3/20 0.41
CES2 O00748 2/20 0.41
TSHR P16473 2/20 0.41
DAO P14920 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 2/20 0.41
XBP1 P17861 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA9 Q16790 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434262 1.00 CYP2C19 (0.43) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL4235762 0.84 CYP2C19 (0.45) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL30018891 0.83 CES2 (0.49) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL311166 0.81 CYP2C19 (0.59) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL21457582 0.81 ALDH1A1 (0.46) CYP2C19KMT2AMEN1ALDH1A1CES1
SCHEMBL6418982 0.79 KMT2A (0.52) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL1898420 0.79 KMT2A (0.52) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL79975 0.79 KMT2A (0.52) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL2882619 0.78 HSD17B10 (0.47) CYP2C19CYP1A2CYP2C9KMT2AMEN1
SCHEMBL15879449 0.78 CLCN2 (0.37) CYP2C19CYP1A2CYP2C9ALDH1A1CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021122039-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2021-06-24 WO claimed
US-10632096-B2 Method of quenching singlet and triplet excited states of photodegradable pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds having electron withdrawing groups, to reduce generation of singlet oxygen HallStar Beauty and Personal Care Innovations Company (US) 2020-04-28 US claimed
EP-3024429-A2 UV COMPOSITIONS HAVING LOW ACTIVE CONCENTRATIONS AND HIGH IN VIVO SPF The Procter & Gamble Company (US) 2016-06-01 EP claimed
US-9351913-B2 SPF liquid cleansing compositions and methods of use COCKERELL DERMATOLOGY DEVELOPMENT, LTD. (US) 2016-05-31 US claimed
US-20150059792-A1 SPF LIQUID CLEANSING COMPOSITIONS AND METHODS OF USE COCKERELL DERMATOLOGY DEVELOPMENT, LTD. 2015-03-05 US claimed
US-8945703-B2 Single- or multilayer, stabilized polyester film MITSUBISHI POLYESTER FILM GMBH (DE) 2015-02-03 US claimed
WO-2015013198-A2 UV COMPOSITIONS HAVING LOW ACTIVE CONCENTRATIONS AND HIGH IN VIVO SPF THE PROCTER & GAMBLE COMPANY (US) 2015-01-29 WO claimed
US-8877166-B2 SPF liquid cleansing compositions COCKERELL DERMATOLOGY DEVELOPMENT, LTD. (US) 2014-11-04 US claimed
EP-1719637-B1 Security document with ultraviolet authentication security feature and method of applying a security feature to a security document. CANADIAN BANK NOTE CO LTD (CA) 2014-06-18 EP claimed
WO-2014025370-A1 TRICYCLIC ENERGY QUENCHER COMPOUNDS FOR REDUCING SINGLET OXYGEN GENERATION HALLSTAR INNOVATIONS CORP. (US) 2014-02-13 WO claimed
EP-0821709-A1 POLYKETONE POLYMER COMPOSITION SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1998-02-04 EP claimed
WO-1996033236-A1 POLYKETONE POLYMER COMPOSITION SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1996-10-24 WO claimed
EP-0601080-B1 FILTERING COSMETIC COMPOSITION CONTAINING A LIPOSOLUBLE FILTER POLYMER WITH HYDROCARBONATED STRUCTURE AND A FILTER SILICONE OREAL (FR) 1995-07-26 EP claimed
EP-0555460-B1 FILTERING COSMETIC COMPOSITION COMPRISING A NANOPIGMENT OF METAL OXIDE AND A LIPOSOLUBLE FILTER POLYMER OREAL (FR) 1995-05-31 EP claimed
EP-0601080-A1 FILTERING COSMETIC COMPOSITION CONTAINING A LIPOSOLUBLE FILTER POLYMER WITH HYDROCARBONATED STRUCTURE AND A FILTER SILICONE. OREAL (FR) 1994-06-15 EP claimed
EP-0581942-A1 ALUMINUM WHEEL CLEARCOAT WITH UV ADDITIVE TO RETARD FILIFORM CORROSION MORTON INTERNATIONAL, INC. (US) 1994-02-09 EP claimed
EP-0555460-A1 FILTERING COSMETIC COMPOSITION COMPRISING A NANOPIGMENT OF METAL OXIDE AND A LIPOSOLUBLE FILTER POLYMER. OREAL (FR) 1993-08-18 EP claimed
WO-1993013875-A1 ALUMINUM WHEEL CLEARCOAT WITH UV ADDITIVE TO RETARD FILIFORM CORROSION MORTON INTERNATIONAL, INC. (US) 1993-07-22 WO claimed
WO-1993004666-A1 FILTERING COSMETIC COMPOSITION COMPRISING A NANOPIGMENT OF METAL OXIDE AND A LIPOSOLUBLE FILTER POLYMER L'OREAL (FR) 1993-03-18 WO claimed
WO-1993004665-A1 FILTERING COSMETIC COMPOSITION CONTAINING A LIPOSOLUBLE FILTER POLYMER WITH HYDROCARBONATED STRUCTURE AND A FILTER SILICONE L'OREAL (FR) 1993-03-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150059792-A1 SPF LIQUID CLEANSING COMPOSITIONS AND METHODS OF USE RARG, STRA6, RARA CYP2C19 3427/4885CYP1A2 3377/4885CYP2C9 3604/4885
US-10632096-B2 Method of quenching singlet and triplet excited states of photodegradable pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds having electron withdrawing groups, to reduce generation of singlet oxygen CBR3, NOX3, CCND3 CYP2C19 1406/4885CYP1A2 1783/4885CYP2C9 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.